Effects of single or repeated silymarin administration on pharmacokinetics of risperidone and its major metabolite, 9-hydroxyrisperidone in rats

Xenobiotica

Volumn 43, Issue 3, 2013, Pages 303-310

  Lee, Hwa Jeong ^a   Lee, Kyoung Sin ^a,b   Chae, Song Wha ^a   Park, Joon Hee ^a   Park, Jung Hyun ^a   Choi, Jong Min ^a   Rhie, Sandy ^a  

^a Ewha Womans University   (South Korea)

^b Korea Food and Drug Administration   (South Korea)

Author keywords

9 hydroxyrisperidone; Bioavailability; Drug interactions; P glycoprotein; Risperidone; Silymarin

Indexed keywords

PALIPERIDONE; RISPERIDONE; SILYMARIN; VERAPAMIL;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; DRUG POTENTIATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; INJECTIONS, INTRAVENOUS; ISOXAZOLES; MALE; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; RISPERIDONE; SILYMARIN;

EID: 84873340432     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2012.731092     Document Type: Article

References (40)

1. Anonymous. (2007). First drug to treat irritability associated with autism. FDA Consum 41:4-4.
2. Achira M, Suzuki H, Ito K, Sugiyama Y. (1999). Comparative studies to determine the selective inhibitors for P-glycoprotein and cytochrome P4503A4. AAPS PharmSci 1:E18.
3. Aravagiri M, Marder SR, Wirshing D, Wirshing WC. (1998). Plasma concentrations of risperidone and its 9-hydroxy metabolite and their relationship to dose in schizophrenic patients: simultaneous determination by a high performance liquid chromatography with electrochemical detection. Pharmacopsychiatry 31:102-109.
4. Ayrton A, Morgan P. (2001). Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica 31:469-497.
5. Bodó A, Bakos E, Szeri F, Váradi A, Sarkadi B. (2003). The role of multidrug transporters in drug availability, metabolism and toxicity. Toxicol Lett 140-141:133-143.
6. Boulton DW, DeVane CL, Liston HL, Markowitz JS. (2002). In vitro P-glycoprotein afnity for atypical and conventional antipsychotics. Life Sci 71:163-169.
7. Cavaliere C, Rea P, Lynch M, Blumenthal M. (2010). Herbal Supplement sales rise in all channels in 2009. HerbalGram 86:62-65.
8. Choi JS, Li X. (2005). The efect of verapamil on the pharmacokinetics of paclitaxel in rats. Eur J Pharm Sci 24:95-100.
9. DiCenzo R, Shelton M, Jordan K, Koval C, Forrest A, Reichman R, Morse G. (2003). Coadministration of milk thistle and indinavir in healthy subjects. Pharmacotherapy 23:866-870.
10. Ereshefsky L, Lacombe S. (1993). Pharmacological profle of risperidone. Can J Psychiatry 38 Suppl 3:S80-S88.
11. Ereshefsky L, Riesenman C, Lam YW. (1995). Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6. Clin Pharmacokinet 29 Suppl 1:10-8; discussion 18.
12. Fromm MF. (2000). P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ter 38:69-74.
13. Fugh-Berman A, Ernst E. (2001). Herb-drug interactions: review and assessment of report reliability. Br J ClinPharmacol 52:587-595.
14. Gazák R, Walterová D, Kren V. (2007). Silybin and silymarin-new and emerging applications in medicine. Curr Med Chem 14:315-338.
15. Gurley BJ, Barone GW, Williams DK, Carrier J, Breen P, Yates CR, Song PF, Hubbard MA, Tong Y Cheboyina S. (2006). Efect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos 34:69-74.
16. Gurley BJ, Swain A, Hubbard MA, Williams DK, Barone G, Hartsfeld F, Tong Y, Carrier DJ, Cheboyina S, Battu SK. (2008). Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: efects of milk thistle, black cohosh, goldenseal, kava kava, St. John's wort, and Echinacea. Mol Nutr Food Res 52:755-763.
17. Han Y Guo D, Chen Y Tan ZR, Zhou HH. (2009). Efect of continuous silymarin administration on oral talinolol pharmacokinetics in healthy volunteers. Xenobiotica 39:694-699.
18. Herbal supplements and remedies: Market research report. (2011). Global Industry Analysts.
19. Hennessy M, Kelleher D, Spiers JP, Barry M, Kavanagh P, Back D, Mulcahy F, Feely J. (2002). St Johns wort increases expression of P-glycoprotein: implications for drug interactions. Br J Clin Pharmacol 53:75-82.
20. Ioannides C. (2002). Pharmacokinetic interactions between herbal remedies and medicinal drugs. Xenobiotica 32:451-478.
21. Johne A, Brockmöller J, Bauer S, Maurer A, Langheinrich M, Roots I. (1999). Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin Pharmacol Ter 66:338-345.
22. Lee CK, Choi JS. (2010). Efects of silibinin, inhibitor of CYP3A4 and P-glycoprotein in vitro, on the pharmacokinetics of paclitaxel after oral and intravenous administration in rats. Pharmacology 85:350-356.
23. Lin JH. (2003). Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. Adv Drug Deliv Rev 55:53-81.
24. Lin JH, Yamazaki M. (2003). Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 42:59-98.
25. Miller, Diane M. (2009). Submission to NIOSH Docket on Hazardous Drug Listing: Risperidone. [Online] Available at: www.cdv.gov/niosh/docket/archive/ pdfs/NIOSH-105-A/0105-A-080709-FariaE-sub.pdf.
26. Mills E, Wilson K, Clarke M, Foster B, Walker S, Rachlis B, DeGroot N, Montori VM, Gold W, Phillips E, Myers S, Gallicano K. (2005). Milk thistle and indinavir: a randomized controlled pharmacokinetics study and meta-analysis. Eur J Clin Pharmacol 61:1-7.
27. Nakagami T, Yasui-Furukori N, Saito M, Tateishi T, Kaneo S. (2005). Efect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition. Clin Pharmacol Ter 78:43-51.
28. Padowski JM, Pollack GM. (2010). Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation. Methods Mol Biol 596:359-384.
29. Palasciano G, Portincasa P, Palmieri V, Ciani D, Vendemiale G, Altomare E. (1994). The efect of silymarin on plasma levels of malon-dialdehyde in patients receiving long-term treatment with psychotropic drugs. Curr Ter Res 55:537-545.
30. Park JH, Park JH, Hur HJ, Woo JS, Lee HJ. (2012). Efects of silymarin and formulation on the oral bioavailability of paclitaxel in rats. Eur J Pharm Sci 45:296-301.
31. Pelkonen O, Turpeinen M, Hakkola J, Honkakoski P, Hukkanen J, Raunio H. (2008). Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol 82:667-715.
32. Pérez-Victoria JM, Pérez-Victoria FJ, Conseil G, Maitrejean M, Comte G, Barron D, Di Pietro A, Castanys S, Gamarro F. (2001). High-afnity binding of silybin derivatives to the nucleotide-binding domain of a Leishmania tropica P-glycoprotein-like transporter and chemosensitization of a multidrug-resistant parasite to daunomycin. Antimicrob Agents Chemother 45:439-446.
33. Piscitelli SC, Burstein AH, Welden N, Gallicano KD, Falloon J. (2002). The efect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis 34:234-238.
34. Posadzki P, Watson L, Ernst E. (2012). Herb-drug interactions: an overview of systematic reviews. Br J Clin Pharmacol doi: 10.1111/J-1365-2125. 2012.04350.x (In Press).
35. Saller R, Meier R, Brignoli R. (2001). The use of silymarin in the treatment of liver diseases. Drugs 61:2035-2063.
36. Saller R, Brignoli R, Melzer J, Meier R. (2008). An updated systematic review with meta-analysis for the clinical evidence of silymarin. Forsch Komplementmed 15:9-20.
37. Tirona RG, Bailey DG. (2006). Herbal product-drug interactions mediated by induction. Br J Clin Pharmacol 61:677-681.
38. Velussi M, Cernigoi AM, De Monte A, Dapas F, Cafau C, Zilli M. (1997). Long-term (12 months) treatment with an anti-oxidant drug (silymarin) is efective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. J Hepatol 26:871-879.
39. Wang JS, Ruan Y, Taylor RM, Donovan JL, Markowitz JS, DeVane CL. (2004). The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein. Int J Neuropsychopharmacol 7:415-419.
40. Wu JW, Lin LC, Hung SC, Chi CW, Tsai TH. (2007). Analysis of silibinin in rat plasma and bile for hepatobiliary excretion and oral bioavailability application. J Pharm Biomed Anal 45:635-641.